AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX) EVP Jason B. Daly Sells 22,000 Shares

Key Points

• Jason B. Daly, EVP of Amneal Pharmaceuticals, sold 22,000 shares of stock for $199,100, representing a 67.47% decrease in his position.
• Amneal Pharmaceuticals recently reported earnings of $0.23 EPS, exceeding analysts' expectations of $0.17 per share.
• Institutional investors hold 31.82% of Amneal's stock, with several large firms recently increasing their stakes in the company.

AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Get Free Report) EVP Jason B. Daly sold 22,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total value of $199,100.00. Following the sale, the executive vice president directly owned 10,606 shares of the company's stock, valued at approximately $95,984.30. This trade represents a 67.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

AMNEAL PHARMACEUTICALS Stock Performance

AMNEAL PHARMACEUTICALS stock traded down $0.09 during trading on Monday, hitting $9.37. The company's stock had a trading volume of 234,676 shares, compared to its average volume of 1,686,029. AMNEAL PHARMACEUTICALS, INC. has a 1-year low of $6.68 and a 1-year high of $9.59. The stock's fifty day moving average is $8.21 and its 200 day moving average is $7.97. The stock has a market capitalization of $2.94 billion, a price-to-earnings ratio of 937.44 and a beta of 1.11.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a negative return on equity of 189.49% and a net margin of 0.12%. On average, research analysts anticipate that AMNEAL PHARMACEUTICALS, INC. will post 0.53 EPS for the current fiscal year.

Institutional Trading of AMNEAL PHARMACEUTICALS

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Sei Investments Co. grew its position in AMNEAL PHARMACEUTICALS by 0.4% in the first quarter. Sei Investments Co. now owns 340,816 shares of the company's stock worth $2,710,000 after acquiring an additional 1,355 shares in the last quarter. Amalgamated Bank lifted its holdings in AMNEAL PHARMACEUTICALS by 33.0% during the 1st quarter. Amalgamated Bank now owns 5,511 shares of the company's stock worth $46,000 after buying an additional 1,367 shares in the last quarter. GF Fund Management CO. LTD. raised its holdings in AMNEAL PHARMACEUTICALS by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 7,934 shares of the company's stock worth $66,000 after purchasing an additional 1,428 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in AMNEAL PHARMACEUTICALS by 16.7% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,107 shares of the company's stock worth $98,000 after purchasing an additional 1,735 shares during the period. Finally, Xponance Inc. increased its holdings in shares of AMNEAL PHARMACEUTICALS by 16.1% in the first quarter. Xponance Inc. now owns 13,183 shares of the company's stock worth $110,000 after acquiring an additional 1,828 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on AMRX shares. The Goldman Sachs Group assumed coverage on AMNEAL PHARMACEUTICALS in a research note on Friday, June 6th. They set a "buy" rating and a $12.00 price target for the company. Wall Street Zen cut AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $11.60.

About AMNEAL PHARMACEUTICALS

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.